Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0457 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| MK-0457 | EXPERIMENTAL | Participants receive MK-0457 as a continuous intravenous infusion (CIV) at assigned dose and duration |
| Name | Type | Description |
|---|---|---|
| MK0457 | DRUG | - |
Inclusion Criteria: Part 1: * Patients with relapsed/refractory acute myelogenous leukemia (AML), poor risk myelodysplastic syndrome (MDS), B-cell acute lymphocytic leukemia (ALL), myeloproliferative diseases, or chronic myelogenous leukemia (CML) in blast crisis Part 2: * Acute myelogenous leuk...
MK0457 is an investigational small molecule being studied for the treatment of Chronic Myelogenous Leukemia in Blast Crisis. It is also being evaluated in related blood cancers including B Cell Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia. The drug is in Phase 1 clinical development.
MK0457 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 1 clinical development for oncology indications.
MK0457 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed, and the drug is no longer in active clinical testing according to available trial records.
MK0457 has been studied in one clinical trial, identified as NCT00111683, titled "MK0457 in Patients With Leukemia (0457-003)". This Phase 1 study enrolled 28 participants and has been completed. The trial was uncontrolled and not randomized or blinded.
MK0457 is the investigational code name for the drug developed by Merck & Company, Inc. No alternative brand names or other designations have been reported for this compound in the available clinical trial information.